Pearl Therapeutics Announces Positive Results From Phase 1 Trial of PT003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial

-- PT003 Demonstrated To Be Safe and Well Tolerated by
Healthy Volunteers in Phase 1 Trial --
REDWOOD CITY, Calif., March 29 /PRNewswire/ -- Pearl
Therapeutics Inc., a company developing clinically differentiated
combination therapies for the...